Stockscreener 앱 받기
27.70
7.87%
2.02
시장 영업 전:
27.02
-0.68
-2.45%
Instil Bio Inc 주식(TIL)의 최신 뉴스
What analysts say about Instil Bio Inc. stockConsistently profitable trades - Jammu Links News
Will Instil Bio Inc. stock benefit from interest rate changesFree Popular Stock Recommendations - Newser
Why Instil Bio Inc. stock attracts strong analyst attentionProtected Capital Trading Plan - Newser
What makes Instil Bio Inc. stock price move sharplyFree Consultation - Newser
How Instil Bio Inc. stock performs during market volatilityTop Growth Low Risk Stocks - Newser
Instil Bio stock jumps after FDA clearance of IND application - Investing.com
Instil Bio stock jumps after FDA clearance of IND application By Investing.com - Investing.com UK
Instil Bio, Inc. Announces U.S. F.D.A. Clearance of Investigational New Drug Application for AXN-2510 - MarketScreener
FDA clears Instil Bio’s IND for AXN-2510 cancer therapy - Investing.com
Instil Bio: Chasing After Summit And BioNTech, Albeit With Some Hiccups - Seeking Alpha
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet - MSN
Instil Bio (TIL) Enhances Axion Bio Board with New Appointment | - GuruFocus
Instil Bio Names John Maraganore, Ph.D., to Board Role - GlobeNewswire
Instil Bio Names John Maraganore, Ph.D., To Board - citybiz
Instil Bio, Inc. Announces the Addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio, Inc., Its Wholly-Owned Subsidiary - MarketScreener
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program - Yahoo Finance
(TIL) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Instil Bio Appoints ‘Seasoned’ Biopharma Exec as Chief Medical Officer - Dallas Innovates
H.C. Wainwright reiterates Instil Bio stock Buy rating amid partnership news By Investing.com - Investing.com South Africa
Instil Bio (TIL) Receives Reiterated Buy Rating from HC Wainwrig - GuruFocus
H.C. Wainwright reiterates Instil Bio stock Buy rating amid partnership news - Investing.com Canada
Instil Bio (TIL) Receives Reiterated Buy Rating from HC Wainwright & Co. | TIL Stock News - GuruFocus
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice - Yahoo Finance
Instil Bio appoints new Chief Medical Officer By Investing.com - Investing.com South Africa
Instil Bio (TIL) Rating Reiterated as Market Perform by JMP Secu - GuruFocus
Instil Bio (TIL) Rating Reiterated as Market Perform by JMP Securities | TIL Stock News - GuruFocus
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire
Instil Bio (TIL) Appoints Jamie Freedman as Chief Medical Officer - GuruFocus
Instil Bio (TIL) Appoints Jamie Freedman as Chief Medical Officer | TIL Stock News - GuruFocus
Instil Bio appoints new Chief Medical Officer - Investing.com
Former Genentech Executive With 15 FDA Approvals Joins Instil Bio to Accelerate Cancer Drug Development - Stock Titan
Instil Bio shares hold as JMP reiterates Market Perform rating By Investing.com - Investing.com India
Instil Bio shares hold as JMP reiterates Market Perform rating - Investing.com Australia
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade - MSN
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference - The Manila Times
Instil Bio CEO Reveals Latest Pipeline Updates at Prestigious Jefferies Healthcare Conference - Stock Titan
Instil Bio Elects Director and Ratifies Auditor - TipRanks
0.64%
0.37%
자본화:
|
볼륨(24시간):